Clinical Trial Update: Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating brolucizumab 6mg in a treat-and-extend regimen for neovascular age-related macular degeneration with prior anti-VEGF exposure was withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Brolucizumab (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-related Macular Degeneration (AMD) | Phase 3 | Status: WITHDRAWN